The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 03, 2020

Filed:

Jan. 27, 2017
Applicants:

Inserm (Institut National DE LA Santé ET DE LA Recherche Médicale), Paris, FR;

Université Toulouse Iii—paul Sabatier, Toulouse, FR;

Centre Hospitalier Universitaire DE Toulouse, Toulouse, FR;

Inventors:

Thierry Levade, Toulouse, FR;

Nicolas Meyer, Toulouse, FR;

Céline Colacios Viatgé, Toulouse, FR;

Caroline Imbert, Toulouse, FR;

Nathalie Andrieu-Abadie, Toulouse, FR;

Bruno Segui, Toulouse, FR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); C07K 16/28 (2006.01); A61K 31/133 (2006.01); A61K 31/137 (2006.01); A61K 31/40 (2006.01); A61K 31/415 (2006.01); A61K 31/4245 (2006.01); A61K 31/426 (2006.01); A61K 31/4535 (2006.01); A61K 45/06 (2006.01); A61K 39/395 (2006.01); G01N 33/569 (2006.01); A61P 35/00 (2006.01); G01N 33/574 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2818 (2013.01); A61K 31/133 (2013.01); A61K 31/137 (2013.01); A61K 31/40 (2013.01); A61K 31/415 (2013.01); A61K 31/426 (2013.01); A61K 31/4245 (2013.01); A61K 31/4535 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); G01N 33/56972 (2013.01); G01N 33/574 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); G01N 2333/70517 (2013.01); G01N 2800/52 (2013.01);
Abstract

The present invention relates to methods for enhancing the potency of the immune checkpoint inhibitors. In particular, the present invention relates to a method for enhancing the potency of an immune checkpoint inhibitor administered to a subject as part of a treatment regimen, the method comprising administering a pharmaceutically effective amount of a SK1 inhibitor to a subject in combination with the immune checkpoint inhibitor.


Find Patent Forward Citations

Loading…